Introduction
============

Cell cycle arrest is a key mechanism that is activated by cellular stress, and is strictly controlled by many regulatory mechanisms that either permit or restrain its progression ([@b1-or-38-01-0031]). The regulatory factors controlling cell cycle progression are cyclins, cyclin-dependent kinases (CDKs), CDK inhibitor (CKI) proteins such as p27 and p21, and tumor suppressor gene products p53 and Rb. Abnormalities of the gene structures (mutations, deletions, or amplifications) and the expression levels of their products are frequently observed in various cancers, which result in cell cycle progression and genetic instability ([@b2-or-38-01-0031]). Thus, correction of the collapse of cell cycle regulation by small-molecule CKIs in these tumors has offered insight that could potentially lead to effective therapeutic strategies. Flavopiridol, a pan-CDK inhibitor, improved response rates in chronic lymphocytic leukemia ([@b3-or-38-01-0031]). Palbociclib, a CDK4 and CDK6 inhibitor, plus fulvestrant prolonged progression-free survival in breast cancer ([@b4-or-38-01-0031]). However, no predictable biomarkers of small-molecule CKIs have been detected.

Recently, CKI proteins involved in G~1~/S arrest have also been shown to induce autophagy ([@b5-or-38-01-0031]--[@b7-or-38-01-0031]). Autophagy is a catabolic process that occurs via the lysosomal degradation pathway. It is essential for cell survival, differentiation, development, and homeostasis. It not only provides nutrients for maintaining vital cellular functions during starvation but also rids cells of superfluous or damaged organelles, misfolded proteins, and invading microorganisms ([@b8-or-38-01-0031]). Autophagy also plays an important role in both tumor progression and tumor suppression ([@b9-or-38-01-0031]). Moreover, autophagy is a survival pathway for cancer cells exposed to genotoxic stress and activated oncogenic signals ([@b10-or-38-01-0031]). Several lines of evidence have indicated that autophagy could be a novel target for cancer treatment. Inhibition of stress-induced autophagy induces apoptotic cell death; therefore, the combination of autophagy inducible stress and autophagy inhibition may provide a synthetic lethal interaction that could become a rational strategy for cancer treatment ([@b11-or-38-01-0031]).

In this study, we examined whether a specific CDK4 inhibitor and a CKI with a broad range of targets (flavopiridol) could induce autophagy in human solid cancer and fibroblast cell lines. Moreover, we examined whether inhibition of the autophagy induced by small-molecule CKIs caused apoptosis in these cell lines.

Materials and methods
=====================

### Cell lines and culture

The following cell lines were used in this study: BT474; MCF7; MDA-MB231; MDA-MB435S; SKBr3 (derived from breast cancer); A431 (derived from epidermoid cancer); NCI-N87 (derived from gastric cancer); SW480 (derived from colorectal cancer); and KMST-6 (derived from a fibroblast). BT474, MDA-MB231, MDA-MB435S, SKBr3, and NCI-N87 were purchased from American Type Culture Collection. A431 and KMST-6 were provided by the Institute of Development, Aging, and Cancer, Tohoku University. SW480 was kindly donated by Professor John M. Mariandason, Ludwig Institute for Cancer Research, Austin Hospital. All cell lines were maintained in RPMI-1640 medium (Sigma-Aldrich, R8758) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, 26140-079) or without FBS (nutrient starvation conditions). The cells were incubated at 37°C in a 5% CO~2~ humidified atmosphere.

### Small-molecule CKIs and autophagy inhibition

CDK4 inhibitor, 2-bromo-12 and 13-dihydro-5 H-indolo-dione \[2 and 3-a\] pyrrolo \[3 and 4-c\] carbazole-5 and 7 (6H)-dione, was purchased from Merck Ltd. (219476-1MG), and flavopiridol was purchased from Santa Cruz Biotechnology, Inc. (sc-202157). Both were dissolved in dimethyl sulfoxide (DMSO) (Wako Pure Chemical Industries Ltd., 043-29355) and added to the cell cultures to make a final concentration of 100 nM. CQ was purchased from Tokyo Kasei Kogyo Co., Ltd. (C2301). To inhibit autophagy, CQ was added to the cell cultures to make a final concentration of 50 µM. ATG5, BECN1, and negative control siRNAs were purchased from Signal Silence, Cell Signaling Technology (\#6345, \#6222, and \#6568). Each siRNA was introduced to the cell cultures to make a final concentration of 100 nM using an X-tremeGENE siRNA transfection reagent (Roche Applied Science Ltd., 4476093).

### Western blot analysis

The lysate was subjected to western blot analysis as previously described ([@b12-or-38-01-0031]). Cells were harvested and resuspended in lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, and 1% protease inhibitor cocktail (Sigma-Aldrich, P2714). Anti-sqstm1 (p62) (Santa Cruz Biotechnology, Inc., sc-28359), anti-β-actin (Sigma-Aldrich, A5316), anti-atg5, anti-beclin-1, anti-LC3 (Medical & Biological Laboratories Co., Ltd., PM036), and anti-cleaved caspase-3 (Cell Signaling Technology, \#2630, \#3738, \#9661) antibodies were used.

### Immunofluorescence analysis

The strategy for LC3 immunofluorescence was described in a previous study ([@b13-or-38-01-0031]). Cells were harvested 18 h after treatment and fixed with 4% paraformaldehyde before incubation for 10 min at room temperature. After washing with Phosphate-buffered saline (PBS) they were permeabilized with 50 µg/ml digitonin (Sigma-Aldrich, D141) for 15 min at room temperature. After a second wash with PBS, the cells were incubated with anti-LC3 diluted 1:250 for 1 h. Subsequently, they were washed with PBS and then incubated with anti-rabbit IgG (H + L) FITC (Beckman Coulter, 732745) for 1 h and visualized using BZ-9000 (Keyence).

### Cell cycle analysis by fluorescence-activated cell sorting (FACS)

A total of 1.5×10^4^ cells per plate were seeded and incubated in 6-cm culture plates for 24 h. The cells were further incubated in the presence of the relevant compounds for 12--72 h. Subsequently, the cells were collected and FACS analysis was performed as previously described ([@b12-or-38-01-0031]).

### Cell proliferation analysis

A total of 5×10^3^ cells per well were seeded and incubated in a 96-well plate for 24 h. They were then treated with the relevant compounds and further cultured at 37°C for 12--72 h. The cell proliferation assays were performed with a Cell Counting Kit-8 (Dojin Laboratories, CK04), as previously described ([@b14-or-38-01-0031]).

### Statistical analysis

Cell cycle analyses were performed independently in triplicate. The data of cell cycle and cell proliferation analyses are presented as mean ± standard deviation (SD). In cell cycle analyses, differences between G~1~ and S phases were analyzed using Student\'s t-test. All statistical analyses were performed using Microsoft Excel^®^. Significant difference was set at p\<0.05.

Results
=======

### Cell cycle arrest and autophagy are induced by nutrient starvation

The aim of this study was to survey the potency of autophagy in eight human solid tumor cell lines, BT474, MDA-MB435S, SKBr3, MCF7, MDA-MB231 (derived from breast cancer), A431 (derived from epidermoid cancer), SW480 (derived from colorectal cancer), and NCI-N87 (derived from gastric cancer), and a human fibroblast, KMST-6. Initially, cell cycle analysis was performed under the condition of nutrient starvation. As shown in [Fig. 1A and B](#f1-or-38-01-0031){ref-type="fig"}, and [Table I](#tI-or-38-01-0031){ref-type="table"}, the G~1~ phase fraction was increased and the S phase fraction was decreased. However, there was no clear change in the sub G~1~ phase fraction. Thus, the nutrient starvation induced cell cycle arrest, but not apoptosis, in all of the cell lines.

Next, the induction of autophagy was monitored under the same conditions by measuring the expression level of p62 protein, which is degraded by autophagy. As shown in [Fig. 1C](#f1-or-38-01-0031){ref-type="fig"}, p62 protein was reduced under the nutrient starvation condition in all of the cell lines. Thus, we concluded that the autophagy induced under starvation was associated with cell cycle arrest.

### CDK4 inhibitor arrests the cell cycle and induces autophagy in some cell lines

To examine whether CDK4 inhibitor arrested cells at the G~1~/S phase in the cell cycle and also induced autophagy, cell cycle progression and p62 expression were analyzed. As shown in [Fig. 2A](#f2-or-38-01-0031){ref-type="fig"} and [Table II](#tII-or-38-01-0031){ref-type="table"}, CDK4 inhibitor arrested cells at the G~1~/S phase in all cell lines, simulating the nutrient starvation condition.

However, under the same condition, p62 degradation was observed only in MDA-MB435S, BT474, SKBr3, A431, and SW480 lines, but not in MCF7, MDA-MB231, NCI-N87, and KMST-6 lines ([Fig. 2B](#f2-or-38-01-0031){ref-type="fig"}). In addition to p62 expression, the formation of LC3 puncta was also observed in MDA-MB435S and BT474 lines, but not in MCF7 and MDA-MB231 ([Fig. 2C](#f2-or-38-01-0031){ref-type="fig"}). Furthermore, the conversion from LC3-I to LC3-II was also observed in MDA-MB435S, but not in MCF7 ([Fig. 2D](#f2-or-38-01-0031){ref-type="fig"}). These findings indicate that autophagy induced by CDK4 inhibitor does not always occur together with G~1~/S arrest, which contrasts with events during nutrient starvation.

To determine whether the autophagy is induced in a dose-dependent manner, p62 degradation assay was performed using MCF7 and KMST-6, in which autophagy was not induced by 100 nM CDK4 inhibitor. As a result, p62 degradation was also not observed in both cell lines, despite the presence of 10 µM CDK4 inhibitor, which is a sufficient concentration to induce G~1~ arrest ([Fig. 2E](#f2-or-38-01-0031){ref-type="fig"}).

We termed the autophagy induced by CDK4 inhibitor the AIC or autophagy induced by CDK4 inhibitor. The AIC status of each cell line was as follows: AIC-positive: BT474, MDA-MB435S, SKBr3, A431, and SW480; AIC-negative: MCF7, MDA-MB231, NCI-N87, and KMST-6.

### Induction of apoptosis by CDK4 inhibitor and CQ

p16, an endogenous CKI, has been shown to induce cytoprotective autophagy ([@b7-or-38-01-0031]). To examine whether autophagy induced by CDK4 inhibitor was also cytoprotective, we performed an analysis of cell proliferation with or without CDK4 inhibitor and/or CQ. CQ is known to be a non-specific autophagy inhibitor. As shown in [Fig. 2B](#f2-or-38-01-0031){ref-type="fig"}, the addition of CQ inhibited p62 degradation by CDK4 inhibitor.

Next, cell proliferation analysis was performed under the same conditions ([Fig. 3A](#f3-or-38-01-0031){ref-type="fig"}). In AIC (+) cell lines (A431 and SW480), the combination of CDK4 inhibitor and CQ inhibited cell proliferation and reduced the number of cells relative to the baseline. In contrast, in AIC (−) cell lines (MCF7 and KMST-6), the combination of these compounds inhibited cell proliferation, but did not reduce the number of cells relative to the baseline. Similar results were also observed in the experiments performed with the other cell lines, excluding NCI-N87 ([Table III](#tIII-or-38-01-0031){ref-type="table"}). To determine the cause of the reduction in the number of cells induced by the combination of CDK4 inhibitor and CQ, cell cycle analysis was performed ([Fig. 3B](#f3-or-38-01-0031){ref-type="fig"}). In AIC (+) cell lines (A431 and SW480), the addition of CQ to CDK4 inhibitor increased the sub-G~1~ fraction. In contrast, in AIC (−) cell lines (MCF7 and KMST-6), the addition of CQ did not change the sub-G~1~ fraction. Similar results were also observed in the experiments performed with the other cell lines ([Table IV](#tIV-or-38-01-0031){ref-type="table"}). These findings indicated that CDK4 inhibitor in combination with CQ induced apoptosis and promoted a synthetic lethal interaction in AIC (+) cell lines, suggesting that the autophagy induced by CDK4 inhibitor may be cytoprotective in these cell lines.

### Induction of apoptosis by CDK4 inhibitor and ATG5 or BECN1 knockdown

To determine whether the induction of apoptosis by the combination of CDK4 inhibitor and CQ was due to the inhibition of autophagy by CQ, we analyzed cell proliferation and cell cycle progression with *ATG5* and *BECN1* siRNA instead of CQ. Atg5 is an E3 ubiquitin ligase which forms a complex with Atg12 and Atg16L1, and this complex is necessary in autophagosome elongation. Beclin-1 interacts with either BCL-2 or the phosphatidylinositol 3 kinase, and shows to be involved in autophagy induction. Both the proteins play critical roles in the regulation of autophagy. As shown in [Fig. 4A](#f4-or-38-01-0031){ref-type="fig"}, siRNA of *ATG5* and *BECN1* suppressed the expression of Atg5 and Beclin-1 proteins, respectively, and also inhibited p62 degradation induced by CDK4 inhibitor in AIC (+) cell lines, which is the same as observed with CQ ([Fig. 4B](#f4-or-38-01-0031){ref-type="fig"}). In AIC (−) cell lines, p62 was not downregulated by CDK4 inhibitor, and *ATG5* and *BECN1* siRNA did not influence p62 protein levels. Next, we examined the expression levels of Atg5 and Beclin-1 by CDK4 inhibitor and CQ. As shown in [Fig. 4C](#f4-or-38-01-0031){ref-type="fig"}, CDK4 inhibitor increased the expression of Atg5 and Beclin-1 proteins in AIC (+) cell lines, but not in AIC (−) cell lines. These results indicated that CDK4 inhibitor induced autophagy via Atg5 and Beclin-1. As shown in [Fig. 4D](#f4-or-38-01-0031){ref-type="fig"}, CQ did not change the expression of Atg5 and Beclin-1 proteins in either AIC (+) or AIC (−) cell lines.

In terms of cell proliferation, a remarkable reduction in the number of cells was observed when CDK4 inhibitor was combined with the knockdown of *ATG5* or *BECN1* in AIC (+) cell lines, but not in AIC (−) cell lines ([Fig. 5A](#f5-or-38-01-0031){ref-type="fig"}, [Table V](#tV-or-38-01-0031){ref-type="table"}). In cell cycle analysis, the combination of CDK4 inhibitor and knockdown of *ATG5* or *BECN1* resulted in an increase in the sub-G~1~ fraction in AIC (+) cell lines, but not in AIC (−) cell lines ([Fig. 5B and C](#f5-or-38-01-0031){ref-type="fig"}, [Table VI](#tVI-or-38-01-0031){ref-type="table"}). These findings indicated that the cytotoxic effect of CQ in AIC (+) cell lines was due to the autophagy inhibition by CQ.

### Confirmation of apoptosis induced by the combination of CDK4 inhibitor and autophagy inhibition

To confirm that the reduction in the number of cells observed when CDK4 inhibitor was combined with autophagy inhibition was due to apoptosis, the production of cleaved caspase-3 was measured. Cleaved caspase-3 was produced when CDK4 inhibitor was combined with autophagy inhibition, by CQ as well as by *ATG5* or *BECN1* knockdown ([Fig. 6](#f6-or-38-01-0031){ref-type="fig"}).

### Induction of apoptosis by the combination of flavopiridol and autophagy inhibition

The aim of this experiment was to determine whether flavopiridol, a small molecule CKI with a broad range of targets, also induced apoptosis in AIC (+) cell lines when the cells were subjected to autophagy inhibition. As shown in [Fig. 7A](#f7-or-38-01-0031){ref-type="fig"}, the addition of flavopiridol to MDA-MB435S cells resulted in p62 degradation. The combination of flavopiridol and autophagy inhibition by either CQ or knockdown of *ATG5* or *BECN1* resulted in an increase in the sub-G~1~ fraction ([Fig. 7B and C](#f7-or-38-01-0031){ref-type="fig"}). Thus, flavopiridol, like CDK4 inhibitor, induced cytoprotective autophagy in the AIC (+) MDA-MB435S cell line.

Discussion
==========

The cell cycle progression of cells deprived of an essential nutrient or growth factor (starvation) or damaged by ionizing radiation or a DNA-damaging agent (genotoxic stress) is blocked at the G~1~/S transition, especially at a point in mid-G~1~ ([@b15-or-38-01-0031]). This point is called the restriction point (R point) and is the point at which the cell becomes 'committed' to the cell cycle because, after this point, extracellular proliferation stimulants are no longer required. In contrast, the cell cycle progression of G~1~ cells that have not reached the R point is immediately arrested. Both starvation and genotoxic stress induce autophagy to maintain homeostasis for survival ([@b8-or-38-01-0031]). Recent research has shown that the expression or activation of CKIs involved in G~1~/S arrest, such as p27, p21, and p16, also induces autophagy ([@b5-or-38-01-0031]--[@b7-or-38-01-0031]). Thus, we hypothesized that cell cycle arrest at the G~1~/S phase was required to induce autophagy and that this was achieved by small-molecule CKIs. In our study, starvation stress resulted in cell cycle arrest at the G~1~/S phase and autophagy in all of the cell lines that we examined. However, small-molecule CKIs only have the ability to induce autophagy in some cell lines \[AIC (+) cell lines\]. It has become clear that autophagy is not necessarily induced by small-molecule CKIs in all solid cancer cells. Furthermore, in KMST-6, a cell line derived from a human fibroblast, autophagy was not induced by CDK4 inhibitor. These results indicate that autophagy induction by CDK4 inhibitor is only a feature of some types of cancer cells. In AIC (−) cell lines, autophagy could be induced by starvation stress but not by CDK4 inhibitors at a dosage sufficiently high to induce cell cycle arrest at the G~1~/S phase. Therefore, we speculate that cell cycle arrest at the G~1~/S phase is necessary but not sufficient for the induction of autophagy.

Several studies have indicated that autophagy promotes cancer cell survival after chemotherapy, radiation therapy, or endocrine therapy ([@b16-or-38-01-0031]--[@b18-or-38-01-0031]). In our study, autophagy inhibition with small-molecule CKIs promoted cell death in AIC (+) cell lines, but not in AIC (−) cell lines, excluding NCI-N87. In NCI-N87, CQ without CDK4 inhibitor reduced the number of cells relative to the baseline. It seems that a concentration of CQ sufficient to induce autophagy is cytotoxic to NCI-N87. These results indicate that autophagy induced by small-molecule CKIs promoted cancer cell survival in the same manner as other anticancer therapies.

Since autophagy is a survival pathway for cancer cells, its inhibition has been considered to be a novel target for cancer treatment ([@b9-or-38-01-0031],[@b18-or-38-01-0031],[@b19-or-38-01-0031]--[@b21-or-38-01-0031]). Although no small-molecule autophagy inhibitors have been developed to date, a number of experiments in cells and animal models have investigated the effects of the anti-malarial agents CQ and hydroxychloroquine (HCQ), which block the degradation of autophagy products by inhibiting lysosomal function ([@b9-or-38-01-0031],[@b20-or-38-01-0031]). Currently, the inhibition of autophagy is thought to contribute to cell death by mechanisms such as stress augmentation ([@b22-or-38-01-0031]) and potentiation of DNA damage ([@b23-or-38-01-0031],[@b24-or-38-01-0031]). The use of an autophagy inhibitor with a genotoxic drug, which includes the majority of cytotoxic agents, might have potential as a novel combination anti-cancer therapy. In addition, the use of an autophagy inhibitor and an inhibitor targeting the PI3K/AKT pathway, such as mTOR, PI3K, and AKT inhibitors, has also been reported as a potentially useful combination in preclinical models ([@b10-or-38-01-0031],[@b22-or-38-01-0031]--[@b24-or-38-01-0031]), as well as clinical trials ([@b9-or-38-01-0031],[@b20-or-38-01-0031]). In this study, we demonstrated that small-molecule CKIs have the ability to induce autophagy and to induce apoptosis in five out of eight cancer cell lines, when combined with autophagy inhibition (CQ or knockdown of *ATG5* or *BECN1*). These findings suggest that the combination therapy with flavopiridol or palbociclib and an autophagy inhibitor such as CQ/HCQ could be a novel antitumor therapy because all have already been tested individually in humans.

If autophagy inhibition is to become a novel target for cancer treatment, then questions arise as to what kind of stress should be combined and which types of cancer are sensitive to autophagy inhibition. According to the Sanger COSMIC Database and our previous study ([@b25-or-38-01-0031]), we did not find an association between AIC status and *p53, Rb1*, and *BECN1* mutations ([Table VII](#tVII-or-38-01-0031){ref-type="table"}). HER2 overexpression and cyclin D1 amplification also seem to have no relationship with AIC status. However, previous studies have suggested that certain cancers are susceptible to autophagy inhibition ([@b10-or-38-01-0031],[@b26-or-38-01-0031]). For example, cancer cells with activation of the KRAS oncogenic signaling pathway exhibit high basal autophagy without any additional stress and are intolerant of other stresses.

The precise molecular mechanisms of autophagy induction by small-molecule CKIs also remain to be elucidated. Orvedahl *et al* reported on the molecules required for autophagy induced by viral infection by performing a comprehensive analysis using an shRNA library ([@b27-or-38-01-0031]). Such high-throughput screening would be useful for detecting the relevant molecules associated with small-molecule CKI-induced autophagy. Once a molecule required for the autophagy induced by small-molecule CKIs is identified, a biomarker predicting the effectiveness of the combination of a small-molecule CKI and an autophagy inhibitor can be developed. At present, the degradation of p62 can act as a surrogate marker to predict subtypes susceptible to synthetic lethal interaction.

In conclusion, the combination of a small-molecule CKI and autophagy inhibition led to a synthetic lethal interaction and induced apoptosis in human solid cancer cell lines susceptible to the autophagy induced by small-molecule CKIs.
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![Analysis of the cell cycle and the autophagy induction potency of nutrient starvation. (A) Cell cycle analysis in RPMI medium supplemented with 10% FBS (normal condition) or no FBS (starvation condition). Each cell line was cultured under normal and starvation conditions for 12 h at 37°C and then cell cycle analysis was performed. The x-axis indicates the phase of the cell cycle. The y-axis indicates the proportion of the cell population. Values shown are mean ± SD (n=3). (A) shows the data for the cell lines MDA-MB435S, BT474, MCF7, and KMST-6. Data for the other cell lines are shown in [Table I](#tI-or-38-01-0031){ref-type="table"}. Differences in G~1~ and S phases between normal and starvation conditions were analyzed using t-test. (B) The images of flow cytometry under conditions matching those for (A). (C) Western blot analysis of p62 under normal and starvation conditions as in (A). Lanes: 1, MDA-MB435S; 2, BT474; 3, SKBr3; 4, A431; 5, SW480; 6, MCF7; 7, MDA-MB231; 8, NCI-N87; 9, KMST-6.](OR-38-01-0031-g00){#f1-or-38-01-0031}

![Analysis of the cell cycle and the autophagy induction potency of CDK4 inhibitor. (A) Cell cycle analysis in the presence of CDK4 inhibitor. Each cell line was cultured for 24 h in the presence of CDK4 inhibitor or DMSO at 37°C and then harvested. CDK4 inhibitor and DMSO were administered at a final concentration of 100 nM. The x-axis indicates the phase of the cell cycle. The y-axis indicates the proportion of the cell population. Values shown are average ± SD (n=3). (A) shows the data for the cell lines MDA-MB435S, BT474, MCF7, and KMST-6. Data for the other cell lines are shown in [Table II](#tII-or-38-01-0031){ref-type="table"}. Differences in the G~1~ and S phases between normal and starvation conditions were analyzed using t-test. CDK4i indicates CDK4 inhibitor. (B) Western blot analysis of p62 during treatment with CDK4 inhibitor and/or CQ. Initially, a final concentration of 50 µM CQ was administered to the cells. After 48 h, a final concentration of 100 nM CDK4 inhibitor or DMSO was administered, and the cells were subsequently cultured for a further 24 h at 37°C before collection for western blotting. (C) Using MDA-MB435S, BT474, MCF7, and MDA-MB231, the formation of LC3 puncta was analyzed by immunofluorescence assay. LC3 immunostaining was performed for the cells treated with CDK4 inhibitor, as described for (A). (D) Using MDA-MB435S and MCF7, western blot analysis of LC3 during treatment with CDK4 inhibitor and/or CQ was performed as described for (A). (E) Using AIC (−) cell lines, MCF7 and KMST-6, western blot analysis of p62 was performed during treatment with CDK4 inhibitor. CDK4 inhibitor or DMSO was administered at a final concentration of 10 nM, 100 nM, 1 µM, or 10 µM, and the cells were subsequently cultured for a further 48 h at 37°C before collection for western blotting.](OR-38-01-0031-g01){#f2-or-38-01-0031}

![Cell proliferation and cell cycle analysis for the combination of CDK4 inhibitor and CQ. (A) After treatment with CDK4 inhibitor and/or CQ as shown in [Fig. 2B](#f2-or-38-01-0031){ref-type="fig"}, cell proliferation analysis was performed. Cell viability just before treatment with CQ was 100%, and the vertical axis corresponds to the absorbance ratio. The x-axis indicates the kind of treatment. The y-axis indicates the proportion of cell proliferation. Values shown are mean ± SD (n=3). (A) shows the data for the cell lines A431, SW480, MCF7, and KMST-6. Data for the other cell lines are shown in [Table III](#tIII-or-38-01-0031){ref-type="table"}. (B) After treatment with CDK4 inhibitor and/or CQ as described for [Fig. 2B](#f2-or-38-01-0031){ref-type="fig"}, cell cycle analysis was performed. The x-axis indicates the phase of the cell cycle. The y-axis indicates the proportion of the cell population. Values shown are mean ± SD (n=3). (B) shows the data for the cell lines A431, SW480, MCF7, and KMST-6. Data for the other cell lines are shown in [Table IV](#tIV-or-38-01-0031){ref-type="table"}. Differences in sub-G~1~ phase between DMSO + CQ and CDK4 inhibitor + CQ were analyzed using t-test. CDK4i, CDK4 inhibitor.](OR-38-01-0031-g02){#f3-or-38-01-0031}

![Analysis of the autophagy inhibition potency of *ATG5* or *BECN1* knockdown. (A) The knockdown efficacy of Atg5 and Beclin-1 using siRNA was determined. Using MDA-MB435S, BT474, SKBr3, A431, SW480, MCF7, and KMST-6, a western blot was performed 48 h after siRNA transfection. 1, MDA-MB435S; 2, BT474; 3, SKBr3; 4, A431; 5, SW480; 6, MCF7; 7, KMST-6. (B) Using the same cell lines as in (A), western blot analysis of p62 was performed following transfection with *ATG5, BECN1*, or negative control siRNA with and without CDK4 inhibitor. Following a 48-h siRNA transfection period, CDK4 inhibitor or DMSO at a final concentration of 100 nM was administered to the cells and they were cultured for 24 h at 37°C before collection for western blotting. (C) Using the same cell lines as in (A), western blot analysis of Atg5 and Beclin-1 was performed after treatment with CDK4 inhibitor. A final concentration of 100 nM CDK4 inhibitor or DMSO was administered to the cells, and these were cultured for 24 h at 37°C before collection for western blotting. 1, MDA-MB435S; 2, BT474; 3, SKBr3; 4, A431; 5, SW480; 6, MCF7; 7, KMST-6. (D) Using the same cell lines as in (A), western blot analysis of Atg5 and Beclin-1 was performed after treatment with CQ. A final concentration of 50 µM CQ or DMSO was administered to the cells, and these were cultured for 24 h at 37°C before collection for western blotting. Lanes: 1, MDA-MB435S; 2, BT474; 3, SKBr3; 4, A431; 5, SW480; 6, MCF7; 7, KMST-6. CDK4i, CDK4 inhibitor.](OR-38-01-0031-g03){#f4-or-38-01-0031}

![Cell proliferation and cell cycle analysis for the combination of CDK4 inhibitor and *ATG5* or *BECN1* knockdown. (A) Cell proliferation analysis under the conditions as described for [Fig. 4B](#f4-or-38-01-0031){ref-type="fig"}. Cell viability just before treatment with siRNA was 100%, and the vertical axis corresponds to the absorbance ratio. The x-axis indicates the type of treatment. The y-axis indicates the proportion of cell proliferation. Values shown are mean ± SD (n=3). (A) shows the data for the cell lines MDA-MB435S, BT474, MCF7, and KMST-6. Data for the other cell lines are shown in [Table V](#tV-or-38-01-0031){ref-type="table"}. 1, DMSO + siControl; 2, DMSO + si*ATG*5; 3, DMSO + si*BECN1*; 4, CDK4i + siControl; 5, CDK4i + si*ATG*5; 6, CDK4i + si*BECN1*. (B) Cell cycle analysis was performed under the conditions as described for (A). The x-axis indicates the phase of the cell cycle. The y-axis indicates the proportion of the cell population. Values shown are mean ± SD (n=3). (B) shows the data for the cell lines MDA-MB435S, BT474, MCF7, and KMST-6. Data for the other cell lines are shown in [Table VI](#tVI-or-38-01-0031){ref-type="table"}. Differences in sub-G~1~ phase between DMSO + siControl and CDK4 inhibitor + siControl, between DMSO + si*ATG5* and CDK4 inhibitor + si*ATG5*, and between DMSO + si*BECN1* and CDK4 inhibitor + si*BECN1* were analyzed using t-test. Lanes: 1, DMSO + siControl; 2, DMSO + si*ATG*5; 3, DMSO + si*BECN1*; 4, CDK4i + siControl; 5, CDK4i + si*ATG*5; 6, CDK4i + si*BECN1*. (C) Images of flow cytometry under the conditions as shown in (B). Lanes: 1, DMSO + siControl; 2, DMSO + si*ATG*5; 3, DMSO + si*BECN1*; 4, CDK4i + siControl; 5, CDK4i + si*ATG*5; 6, CDK4i + si*BECN1*. CDK4i, CDK4 inhibitor.](OR-38-01-0031-g04){#f5-or-38-01-0031}

![Apoptosis analysis for the combination of CDK4 inhibitor and autophagy inhibition by cleaved caspase-3 assay. Using AIC (+) cell lines, MDA-MB435S and BT474, a cleaved caspase-3 assay was performed under the conditions as described in [Figs. 2B](#f2-or-38-01-0031){ref-type="fig"} and [5B](#f5-or-38-01-0031){ref-type="fig"}. CDK4i, CDK4 inhibitor.](OR-38-01-0031-g05){#f6-or-38-01-0031}

![Cell cycle analysis for the combination of flavopiridol and autophagy inhibition in MDA-MB435S cell line. (A) Western blot analysis of p62 was performed following treatment with flavopiridol, instead of CDK4 inhibitor and autophagy inhibition, under the same conditions as described in [Fig. 6](#f6-or-38-01-0031){ref-type="fig"}. (B) Cell cycle analysis under the conditions as described for (A). The x-axis indicates the phase of the cell cycle. The y-axis indicates the proportion of the cell population. Values shown are mean ± SD (n=3). D, DMSO; F, flavopiridol. (C) Images of flow cytometry under the conditions as in (B).](OR-38-01-0031-g06){#f7-or-38-01-0031}

###### 

Analysis of the cell cycle of the nutrient starvation.

  Cell line    FBS (%)   sub-G~1~ (%)   G~1~ (%)   p-value   S (%)      p-value   G~2~/M (%)
  ------------ --------- -------------- ---------- --------- ---------- --------- ------------
  BT474        10        1.1±0.4        54.7±4.7   \<0.01    35.6±3.9     0.03      8.6±3.4
                 0       1.7±0.1        68.0±4.3             19.9±3.2             10.4±6.7
  MDA-MB435S   10        0.9±0.5        57.5±4.4     0.01    31.8±1.9     0.02      9.8±5.8
                 0       1.3±0.5        71.5±6.1             17.0±4.6             10.2±4.9
  SKBr3        10        1.9±0.3        52.0±5.9   \<0.01    31.9±2.4     0.01    14.2±4.0
                 0       3.0±0.8        68.8±2.7             13.5±2.4             14.7±4.7
  A431         10        2.3±0.6        58.0±4.9     0.01    32.6±4.6   \<0.01      7.1±3.5
                 0       2.5±0.7        68.0±5.0             20.0±2.8               9.5±3.1
  SW480        10        1.3±0.3        63.0±4.4   \<0.01    28.3±3.8     0.02      7.4±1.7
                 0       1.7±0.3        70.6±4.8             17.1±3.9             10.6±1.3
  MCF7         10        2.2±0.6        54.7±1.4     0.04    36.9±2.1     0.01      6.2±2.9
                 0       2.0±1.5        64.8±6.6             23.3±3.9               9.9±4.2
  MDA-MB231    10        2.4±0.7        66.8±2.4     0.01    24.2±5.8     0.01      6.6±4.1
                 0       4.0±1.5        78.8±3.7             11.0±2.7               6.2±0.5
  NCI-N87      10        1.6±0.4        56.4±5.3   \<0.01    33.3±3.1     0.01      8.7±2.6
                 0       2.2±0.4        67.0±4.1             23.3±4.8               7.5±1.1
  KMST-6       10        1.2±0.5        66.0±4.3     0.01    28.0±1.9     0.03      4.8±2.9
                 0       1.5±0.6        76.9±3.6             15.8±3.6               5.8±4.1

Data are expressed as mean ± SD. G~1~ and S fractions were examined paired t-test between FBS 10% and FBS 0%.

###### 

Analysis of the cell cycle of CDK4 inhibitor.

  Cell line    Condition   sub-G~1~ (%)   G~1~ (%)   p-value   S (%)      p-value   G~2~/M (%)
  ------------ ----------- -------------- ---------- --------- ---------- --------- ------------
  BT474        DMSO        1.5±0.4        64.6±5.0     0.01    20.6±3.3   \<0.01    13.3±2.1
               CDK4i       2.6±1.1        81.9±1.2             11.1±1.8               4.4±1.7
  MDA-MB435S   DMSO        1.1±0.3        49.9±7.6     0.03    40.2±5.5     0.03      8.8±2.4
               CDK4i       2.1±0.9        69.9±8.7             19.9±4.6               8.1±5.0
  SKBr3        DMSO        5.0±1.4        51.6±4.4   \<0.01    36.3±3.5   \<0.01      7.1±0.5
               CDK4i       3.9±1.7        59.6±3.0             23.6±1.6             12.9±0.3
  A431         DMSO        2.8±0.7        51.1±1.9     0.02    35.9±2.6     0.04    10.2±1.4
               CDK4i       3.0±0.7        63.5±3.2             26.0±2.6               7.5±1.3
  SW480        DMSO        2.6±0.6        60.4±3.6     0.01    29.1±1.9   \<0.01      7.9±2.3
               CDK4i       2.9±0.9        70.7±3.4             18.0±1.7               8.5±2.6
  MCF7         DMSO        0.9±0.2        61.8±2.5     0.01    31.8±2.4   \<0.01      5.5±0.3
               CDK4i       0.8±0.2        74.7±2.5             16.9±2.3               7.6±0.4
  MDA-MB231    DMSO        1.1±0.2        63.9±3.6   \<0.01    28.5±1.7   \<0.01      6.5±2.1
               CDK4i       1.1±0.4        78.5±5.5             15.4±3.3               5.1±2.6
  NCI-N87      DMSO        2.0±0.6        61.0±1.3   \<0.01    28.8±2.0   \<0.01      8.2±2.7
               CDK4i       2.3±0.6        74.6±2.0             14.8±2.4               8.2±3.8
  KMST-6       DMSO        0.9±0.2        60.4±3.4     0.01    29.4±2.5     0.01      9.3±1.1
               CDK4i       0.9±0.3        78.4±2.8             13.9±3.3               6.8±0.8

Data are expressed as mean ± SD. G~1~ and S fractions were examined paired t-test between DMSO and CDK4 inhibitor (CDK4i).

###### 

Cell proliferation analysis for the combination of CDK4 inhibitor and CQ.

  Cell line      DMSO     DMSO + CQ   CDK4i    CDK4i + CQ
  -------------- -------- ----------- -------- ------------
  AIC (+)                                      
    BT474        348±59   310±49      150±39     72±19
    MDA-MB435S   286±86   187±55      137±49     71±27
    SKBr3        210±50   150±77      111±39     49±13
    A431         330±67   288±48      126±39     37±19
    SW480        247±60   219±43      119±22     50±13
  AIC (−)                                      
    MCF7         329±58   260±69      149±43     98±19
    MDA-MB231    295±69   210±58      140±39   120±44
    NCI-N87      198±76     80±44     113±33     51±29
    KMST-6       238±40   221±54      110±31   120±54

Absorbance of 72 h/absorbance of 0 h × 100%. Data are expressed as mean ± SD. AIC, autophagy induced by CDK4 inhibitor; CQ, chloroquine; DMSO, dimethyl sulfoxide; CDK4i, CDK4 inhibitor.

###### 

Cell cycle analysis for the combination of CDK4 inhibitor and CQ.

  Cell line      Condition    sub-G~1~ (%)   p-value   G~1~ (%)   S (%)      G~2~/M (%)
  -------------- ------------ -------------- --------- ---------- ---------- ------------
  AIC (+)                                                                    
    BT474        DMSO + CQ      2.6±0.8      \<0.01    68.4±3.7   20.2±4.4     8.8±1.5
                 CDK4i + CQ   28.9±2.9                 55.8±5.1   8.9±0.7      6.4±2.9
    MDA-MB435S   DMSO + CQ      4.0±1.6      \<0.01    56.4±2.9   33.6±4.0     6.0±2.7
                 CDK4i + CQ   16.6±3.5                 51.0±1.5   23.7±1.3     8.7±3.7
    SKBr3        DMSO + CQ      7.6±1.7        0.02    49.3±5.1   35.3±4.6     7.8±2.2
                 CDK4i + CQ   23.7±3.9                 40.7±5.0   24.4±1.1   11.2±2.1
    A431         DMSO + CQ      4.1±3.2        0.03    48.8±5.2   36.6±2.9   10.5±0.9
                 CDK4i + CQ   19.9±4.4                 46.6±5.3   24.9±4.2     8.6±3.3
    SW480        DMSO + CQ      4.3±2.5        0.01    59.5±9.1   26.8±9.9     9.4±1.7
                 CDK4i + CQ   27.2±3.5                 47.8±4.6   17.0±1.7     8.0±2.8
  AIC (−)                                                                    
    MCF7         DMSO + CQ      3.8±1.4        0.15    52.2±3.7   30.9±2.8   13.1±4.2
                 CDK4i + CQ     3.2±1.2                66.2±4.7   18.5±2.6   12.1±3.3
    MDA-MB231    DMSO + CQ      1.7±0.6        0.28    62.6±3.9   29.9±3.2     5.8±1.5
                 CDK4i + CQ     1.9±0.2                77.2±3.8   15.7±3.8     5.2±0.2
    NCI-N87      DMSO + CQ      2.3±0.9        0.45    60.7±5.2   29.0±2.9     8.0±3.2
                 CDK4i + CQ     2.4±0.7                75.7±3.1   14.0±2.2     7.9±1.6
    KMST-6       DMSO + CQ      1.6±0.3        0.09    62.6±5.5   27.6±3.5     8.2±2.3
                 CDK4i + CQ     3.0±1.2                74.7±2.4   13.6±3.5     8.7±4.7

Data are expressed as mean ± SD. sub-G~1~ fraction was examined paired t-test between DMSO + CQ and CDK4 inhibitor (CDK4i) + CQ. AIC, autophagy induced by CDK4 inhibitor.

###### 

Cell proliferation analysis for the combination of CDK4 inhibitor and *ATG5* or *BECN1* knockdown.

  Cell line      DMSO + siControl   DMSO + si*ATG5*   DMSO + si*BECN1*   CDK4i + siControl   CDK4i + si*ATG5*   CDK4i + si*BECN1*
  -------------- ------------------ ----------------- ------------------ ------------------- ------------------ -------------------
  AIC (+)                                                                                                       
    BT474        247±52             194±45            155±74             116±15              67±2               64±9
    MDA-MB435S   208±10             123±14            116±22             108±23              55±22              49±14
    SKBr3        171±25             129±21            116±25             118±14              62±16              65±19
    A431         248±39             225±31            205±16             128±7               67±4               76±39
    SW480        264±55             222±42            219±13             123±15              51±9               60±16
  AIC (−)                                                                                                       
    MCF7         224±5              196±46            191±5              133±26              141±26             125±13
    KMST-6       210±28             189±15            194±29             130±13              137±15             122±12

Absorbance of 72 h/absorbance of 0 h ×100%. Data are expressed as mean ± SD. AIC, autophagy induced by CDK4 inhibitor; DMSO, dimethyl sulfoxide; CDK4i, CDK4 inhibitor.

###### 

Cell cycle analysis for the combination of CDK4 inhibitor and *ATG5* and *BECN1* knockdown.

  Cell line      Condition           sub-G~1~ (%)   p-value   G~1~ (%)   S (%)      G~2~/M (%)
  -------------- ------------------- -------------- --------- ---------- ---------- ------------
  AIC (+)                                                                           
    BT474        DMSO + siControl      1.4±0.6      --        64.9±3.5   23.3±5.6   10.4±2.7
                 DMSO + si*ATG5*       3.9±2.4      --        62.9±4.6   21.9±5.8   11.3±1.2
                 DMSO + si*BECN1*      3.3±0.8      --        65.0±6.0   21.8±5.4     9.9±0.2
                 CDK4i + siControl     2.9±1.2        0.09    82.9±2.9   10.1±2.4     4.1±0.7
                 CDK4i + si*ATG5*    22.2±3.5       \<0.01    59.0±3.6   10.9±1.5     7.9±1.4
                 CDK4i + si*BECN1*   25.1±2.4       \<0.01    62.1±3.8   11.2±1.8     1.6±0.4
    MDA-MB435S   DMSO + siControl      2.0±0.6      --        55.6±2.7   35.9±2.1     6.5±4.2
                 DMSO + si*ATG5*       2.7±0.2      --        56.6±5.4   34.0±2.0     6.7±3.6
                 DMSO + si*BECN1*      3.7±1.0      --        56.9±1.5   34.5±2.4     4.9±2.9
                 CDK4i + siControl     2.7±0.8        0.13    64.9±8.4   23.0±4.0     9.4±5.2
                 CDK4i + si*ATG5*    17.7±2.7       \<0.01    51.5±3.6   22.5±0.6     8.3±5.7
                 CDK4i + si*BECN1*   14.2±5.1         0.03    56.7±7.6   22.1±3.3     7.0±0.8
    SKBr3        DMSO + siControl      6.3±1.1      --        52.8±3.5   31.3±2.8     9.6±5.2
                 DMSO + si*ATG5*       6.6±1.0      --        51.8±8.3   34.3±4.5     7.3±4.8
                 DMSO + si*BECN1*      5.7±1.1      --        53.6±3.9   32.0±2.6     8.7±2.4
                 CDK4i + siControl     3.9±2.0        0.09    58.9±3.1   23.7±2.0   13.5±0.9
                 CDK4i + si*ATG5*    21.1±4.4       \<0.01    40.7±1.8   24.7±4.7   13.4±1.8
                 CDK4i + si*BECN1*   19.0±6.6         0.04    42.2±3.4   23.9±4.8   14.9±1.6
    A431         DMSO + siControl      3.5±0.9      --        52.0±4.5   34.1±3.8   10.4±0.2
                 DMSO + si*ATG5*       4.3±0.5      --        48.4±3.6   36.5±2.9   10.8±1.2
                 DMSO + si*BECN1*      3.1±1.9      --        50.2±4.2   35.7±3.0   11.0±3.1
                 CDK4i + siControl     3.6±0.3        0.42    62.6±2.5   24.7±2.4     9.1±0.4
                 CDK4i + si*ATG5*    16.8±6.9         0.04    52.4±6.2   22.1±2.8     8.7±2.1
                 CDK4i + si*BECN1*   18.3±4.2       \<0.01    49.6±3.1   25.7±2.2     6.3±0.9
    SW480        DMSO + siControl      2.7±0.4      --        61.7±3.9   27.3±2.7     8.3±1.6
                 DMSO + si*ATG5*       3.7±2.5      --        58.9±4.0   28.9±3.3     8.5±1.8
                 DMSO + si*BECN1*      2.8±0.9      --        63.1±3.6   26.5±4.1     7.6±1.4
                 CDK4i + siControl     3.4±2.5        0.35    70.6±5.4   16.9±4.4     9.1±1.5
                 CDK4i + si*ATG5*    23.4±4.3       \<0.01    50.6±4.1   18.6±2.2     7.4±2.4
                 CDK4i + si*BECN1*   22.5±4.0       \<0.01    51.4±3.1   17.7±2.0     8.5±3.0
  AIC (−)                                                                           
    MCF7         DMSO + siControl      2.6±0.7      --        61.9±1.6   28.8±1.6     6.7±0.9
                 DMSO + si*ATG5*       4.6±0.6      --        56.2±1.8   29.1±2.9   10.1±2.2
                 DMSO + si*BECN1*      4.6±1.3      --        55.1±1.7   32.0±3.3     8.3±2.0
                 CDK4i + siControl     2.0±0.8        0.37    72.6±2.8   17.8±4.7     7.6±2.4
                 CDK4i + si*ATG5*      2.3±1.0        0.06    67.1±2.0   21.1±2.2     9.5±4.4
                 CDK4i + si*BECN1*     2.5±1.0        0.07    66.8±4.9   21.2±4.1     9.5±5.4
    KMST-6       DMSO + siControl      1.0±0.4      --        62.2±2.5   29.2±2.9     7.6±1.6
                 DMSO + si*ATG5*       1.1±0.5      --        60.7±3.4   29.9±2.4     8.3±1.8
                 DMSO + si*BECN1*      1.1±0.4      --        61.0±4.3   28.6±6.3     9.3±3.6
                 CDK4i + siControl     0.9±0.2        0.34    76.1±2.4   14.6±2.0     8.4±0.3
                 CDK4i + si*ATG5*      2.9±1.2        0.06    73.3±2.0   14.6±3.0     9.2±5.3
                 CDK4i + si*BECN1*     3.8±2.9        0.12    73.5±3.7   13.8±1.6     8.9±4.2

Data are expressed as mean ± SD. AIC, autophagy induced by CDK4 inhibitor; DMSO, dimethyl sulfoxide; CDK4i, CDK4 inhibitor. Sub-G~1~ fraction was examined paired t-test, between DMSO + siControl and CDK4i + siControl, between DMSO + si*ATG5* and CDK4i + si*ATG5*, and between DMSO + si*BECN1* and CDK4i + si*BECN1*.

###### 

The characteristics of cell lines used in this study.

  Cell line      Origin       *p53*   *Rb1*    *BECN1*   HER2 overexpression   Cyclin D1 amplification
  -------------- ------------ ------- -------- --------- --------------------- -------------------------
  AIC (+)                                                                      
    BT474        Breast       Mut     LOH      LOH       (+)                   (+)
    MDA-MB435S   Breast       Mut     LOH      LOH       (+)                   (−)
    SKBr3        Breast       Mut     Normal   Normal    (+)                   (−)
    A431         Epidermis    Mut     LOH      Normal    ND                    (+)
    SW480        Colon        Mut     Normal   Normal    ND                    (+)
  AIC (−)                                                                      
    MCF7         Breast       wt      LOH      LOH       (−)                   (+)
    MDA-MB231    Breast       Mut     LOH      LOH       (−)                   (+)
    NCI-N87      Stomach      Mut     Normal   Normal    (+)                   (−)
    KMST-6       Fibroblast   wt      Normal   Normal    ND                    (−)

AIC, autophagy induced by CDK4 inhibitor; Mut, mutant type; wt, wild-type; LOH, loss of heterozygosity; ND, not determined.
